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Biomarker testing has become standard of care for patients diagnosed with non-small cell
lung carcinoma (NSCLC). Although, it can be successfully performed in circulating tumor
cells, at present, the vast majority of investigations are carried out using direct tumor
sampling, either through aspiration methods, which render most often isolated cells, or
tissue sampling, that could range from minute biopsies to large resections. Consequently,
pathologists play a central role in this process. Recent evidence suggests that refining
NSCLC diagnosis might be clinically significant, particularly in cases of lung adenocarcino-
mas (ADC), which in turn, has prompted a new proposal for the histologic classification of
such pulmonary neoplasms. These changes, in conjunction with the mandatory incorpo-
ration of biomarker testing in routine NSCLC tissue processing, have directly affected the
pathologist’s role in lung cancer work-up. This new role pathologists must play is complex
and demanding, and requires a close interaction with surgeons, oncologists, radiologists,
and molecular pathologists. Pathologists often find themselves as the central figure in
the coordination of a process, that involves assuring that the tumor samples are properly
fixed, but without disruption of the DNA structure, obtaining the proper diagnosis with a
minimum of tissue waste, providing pre-analytical evaluation of tumor samples selected
for biomarker testing, which includes assessment of the proportion of tumor to normal
tissues, as well as cell viability, and assuring that this entire process happens in a timely
fashion.Therefore, it is part of the pathologist’s responsibilities to assure that the samples
received in their laboratories, be processed in a manner that allows for optimal biomarker
testing.This article goal is to discuss the essential role pathologists must play in NSCLC bio-
marker testing, as well as to provide a summarized review of the main NSCLC biomarkers
of clinical interest.
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INTRODUCTION
In Canada, lung cancer represents the second most common can-
cer in both males and females (14 and 13%, respectively), and it is
the leading cause of cancer death for both sexes (1). In fact, lung
cancer, with 27.2 and 26.3% mortality rate in males and females,
respectively, is responsible for more deaths among Canadians than
the other two leading organ-specific cancers combined [colorectal
(12.7%) and prostate (10.0%) in males, and breast (13.9%) and
colorectal (11,6%) in females] (1). In the United States, approx-
imately 84% of new lung cancer cases are classified as non-small
cell lung carcinomas (NSCLC), and 15% as small cell carcino-
mas (SCC) (2), with the majority of patients being diagnosed at
advanced-stage (56%) (3). The prognosis is poor, with the overall
5-year survival rate of 6.1% for SCC and 17.1% for NSCLC (2).
Implementation of personalized targeted therapies has become
a reality for a group of lung cancer patients, but this therapeutic
Abbreviations: NSCLC, non-small cell lung carcinoma; SCC, small cell carcino-
mas; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase;
ADC, adenocarcinoma; LGC, large cell carcinoma; SqCC, squamous cell carcinoma;
TKI, tyrosine kinase inhibitors; TAT, turn-around-time; ALCL, anaplastic large cell
lymphomas; FISH, fluorescence in situ hybridization.
option is usually reserved for those patients whom tumor sam-
ples have been screened for specific biomarkers. A multitude
of potentially useful biomarkers have recently emerged and this
list continues to grow. It has become increasingly difficult for
pathologists and oncologists to define which biomarkers should
be routinely tested. An expert panel in pathology and oncol-
ogy, assembled by the College of American Pathologists (CAP)
with representatives from the International Association for the
Study of Lung Cancer (IASLC) and Association for Molecular
Pathology (AMP), has recently met in an attempt to address ques-
tions regarding biomarker testing in lung cancer. The conclusions
have been published in the format of testing guidelines, which
presently recommends investigations of abnormalities involving
only two genes: the epidermal growth factor receptor (EGFR) and
the anaplastic lymphoma kinase (ALK ) (4).
This review will focus on the role of the pathologist as an
essential figure in the NSCLC biomarker testing process.
TISSUE/CYTOLOGICAL DIAGNOSIS AND BIOMARKER
TESTING
NSCLC, as a standing alone diagnosis, in either tissue or cyto-
logical samples, should be avoided whenever possible. In some
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situations (when the tumor sample is restricted to a smear from
a bronchial brushing of a poorly differentiated carcinoma, for
example), further characterization might be impossible. However,
in our experience, further characterization, particularly with the
help of special histochemical stains for the detection of mucin
(often with the use of PAS-D or mucicarmin), and/or immuno-
cytochemistry, can be achieved in the majority of cases. From
a practical point of view, samples containing adenocarcinoma
(ADC) either pure or mixed should undergo biomarker testing.
In small samples, the recommendations are less stringent, and, as
long as an ADC component cannot be excluded, the tissue should
undergo biomarker testing (irrespective of the main tumor com-
ponent identified). In resections, however, when the pathologist
has an opportunity to examine the lesion in its entirety, “pure”
tumors [large cell carcinoma (LGC), squamous cell carcinoma
(SqCC) or others] should not be tested (Figure 1).
Numerous immunomarkers are available in order to help in the
sub classification of NSCLC. The most commonly used are TTF-1,
Napsin-A, p63, CK 5/6, and p40 (5–13). Although, it is true that in
most cases the pathologist will be reasonably at ease to sub classify
NSCLC’s, in some cases, sub classification might be rather difficult.
It is our understanding that if the pathologist is uncertain about
the specific sub classification, then the sample should be submitted
for biomarker testing.
Despite the emphasis placed on focusing on ADC for biomarker
testing, it is important to highlight that there are, however, isolated
reports in the literature of the detection of either EGFR mutations
or ALK rearrangements in tumors classified as SqCC (14–17).
Interestingly, some genetic aberrations can be generally asso-
ciated with specific NSCLC subtypes and/or clinical profile (i.e.,
smokers versus non-smokers) (18). ADC is the predominant his-
tologic type associated with both EGFR-mutated, as well as in
ALK -rearranged cases. However, EGFR mutations are particu-
larly prevalent in those cases containing non-mucinous bron-
chioloalveolar (lepidic) pattern (19), while in ALK-rearranged
ADC, the most striking correlation is made with the presence of a
signet-ring component (Table 1) (20, 21).
An important aspect that affects biomarker testing is the
amount of available tumor present in a determined sample. This
is a rather difficult topic to address, since the test sensitivity varies
significantly according to the employed technique, particularly
when searching for EGFR mutations, where normal DNA might
interfere with test sensitivity (22). Nevertheless, the pathologist
should provide an estimation of the percentage of tumor present
in the sample, as well as, the viability of the tumor cells. It is
recommended that testing sensitivity, as well as determination
of limiting factors that might influence optimal results (fixative
choice for example), should be defined locally, through proper
validation methods. Of note, samples collected from aspiration
biopsy methods, including direct lesion sampling (transbronchial
needle aspiration biopsies), as well as the drainage of effusions,
should be considered for biomarker testing (23–25).
FIGURE 1 | Recommendations on specimen handling in NSCLC biomarker testing.
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Table 1 | Summary of the clinical characteristics, common genetic abnormalities and respective targeting agents of the main NSCLC biomarkers.
Biomarkers Gender and age Prevalence Tobacco Ethnicity ADC versus SqCC/distinctive
histologic characteristics
Clinically relevant
genetic abnormality
Examples of targeting agent
(available or in development)
EGFR Female, Younger 10-40% Non-smokers Asian ADC/Non-mucinous
bronchioloalveolar (lepidic)
Mutation (various, most
common in-frame deletions of
exon 19 and a point mutation
(CTG to CGG) in exon 21)
Gefitinib, Erlotinib, Afatinib,
Dacomitinib, Neratinib
ALK Younger 2-6% Non-smokers Not distinctive ADC/solid pattern, signet-ring
cells
Translocation, inversion
(EML4-ALK most common)
Crizotinib, LDK378
HER2/ERBB2 Female 1-4% Non-smokers Asians ADC In-frame insertions in exon 20 Trastuzumab Pertuzumab,
Lapatinib
ROS1 Female, younger 0,5-2% Non-smokers Und. ADC Translocation (ROS1-FIG) Crizotinib
RET Younger 1-2% Non-smokers Not distinctive ADC/Adenosquamous KIF5B–RET and CCDC6–RET
fusion genes
Vandetanib Cabozantinib
KRAS Not distinctive 15-30% Smokers Caucasian ADC/mucinous, particularly with
lepidic (bronchioloalveolar)
pattern
Mutations in codon 12 (majority)
and 13
Selumetinib (via inhibition of
MEK)
BRAF Not distinctive 3% (ADC’s) Smokers Not distinctive ADC Mutations in, V600E(50%),
G469A(39%), D594G(11%)
Dabrafenib, Vemurafenib, XL281,
Selumetinib
NRAS Und. 0.5-1% Smokers Und. ADC Mutations in codon Q61 in exon
3 (80%) and G12 (exon 2)
Selumetinib Trametinib
FGFR1 Not distinctive 22% of SqCC Smokers Not distinctive SqCC Amplification PD173074
PTEN Not distinctive 4-8% Smokers Not distinctive SqCC Various mutations in exon 5-8 GSK2636771
DDR2 Und. 2.5-3.8% Und. Und. SqCC Missense mutations, several Imatini, Dasatinib
MAP2K1/MEK1 Und. 1% Unclear Und. ADC Mutations in Q56P, K57N and
D67N
AZD6244, Pimasertib,
Refametinib, others
PIK3CA Not distinctive 2-4% Mixed
reports
Not distinctive ADC and SqCC Mutations in E545K AND
H1047R (most common), also
E542K and H1047L
Everolimus, Tensirolimus,
GDC-0941, XL-147, Others
AKT1 Und. 1% Und. Und. ADC and SqCC Mutation in E17K MK-2206
MET Not distinctive 1-5% Not
distinctive
Und. ADC Amplification, protein
overexpression and mutation
Vandetanib, Cabozantinib
Und: undetermined.
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EPIDERMAL GROWTH FACTOR RECEPTOR
Epidermal growth factor receptor (also known as HER-1 or
Erb1) is a member of the ErbB receptor tyrosine kinase fam-
ily, which also includes HER-2/neu (ErbB2), HER-3 (ErbB3), and
HER-4 (ErbB4). EGFR activation is associated with cancer cell
growth, invasion, proliferation, apoptosis, tumor angiogenesis,
and metastatic spread. Therefore, it plays an important role in
carcinogenesis and tumor progression by activation mechanisms,
including overexpression, mutation, and autocrine ligand produc-
tion. These actions are accomplished through activation of the
RAS/RAF/MEK/MAPK and the PI3K/AKT/mTOR pathways (26).
The two most common EGFR activating mutations that confer
sensitivity to tyrosine kinase inhibitors (TKI) are short in-frame
deletions of exon 19, and a point mutation (CTG to CGG) in exon
21 at nucleotide 2573, that results in substitution of leucine by argi-
nine at codon 858 (L858R) (27). Despite the fact that these two
mutations might represent approximately 90% of all known clini-
cally significantEGFR mutations, the consensus recommendations
are that all EGFR mutations that account for at least 1% should
be tested (4). It is important to emphasize that among the tested
mutations, exon 20 T790M, as well as most exon 20 insertions are
associated with resistance to first-generation TKI’s (28).
Epidermal growth factor receptor mutations occur at a higher
frequency in tumors from East Asians than from non-Asians (30
versus 8%), from women than from men (59 versus 26%), from
never smokers than from ever smokers (66 versus 22%), and in
ADC’s compared with other NSCLC histologies (49 versus 2%)
(29). In the United States, it is estimated that activating EGFR
mutations are found in 15% of patients with primary lung ADC
(Table 1) (30).
Turn-around-time (TAT) might be a very important factor for
advanced-stage patients, whom might benefit from early insti-
tution of targeted therapy. The consensus recommends a maxi-
mum of 10 working days as an acceptable TAT from the date the
laboratory receives the sample to be tested (4).
ANAPLASTIC LYMPHOMA KINASE
Translocations involving ALK have previously been identified in
anaplastic large cell lymphomas (ALCL), and in a rare mesenchy-
mal neoplasm known as inflammatory myofibroblastic tumor or
inflammatory pseudotumor (31, 32). In lung carcinomas, ALK
rearrangement was first demonstrated in 2007 by Soda et al. (33)
when ALK fusion transcripts were found in 6.7% (5 out of 75) of
NSCLC samples. However, the prevalence of ALK rearrangement
in lung carcinomas varies significantly (34–36).
ALK rearrangements tend to be mutually exclusive with other
known driver mutations in NSCLC (18). However, it has rarely
been described together with EGFR and PI3K mutations (36–38).
ALK -rearranged NSCLC patients, when compared to ALK -
non-rearranged, are more frequently non- or light-smokers,
younger, and present with advanced clinical stage. Histologically,
the tumors demonstrate most frequently ADC with solid pattern
and signet-ring cells (20, 21, 39).
Although fluorescence in situ hybridization (FISH) is currently
the gold standard method for detecting ALK rearrangements
according to the United States Food and Drug Administration
(FDA) (40), the CAP consensus accepts that, if carefully validated,
immunohistochemistry can be considered as a screening method
(4). This proposition is in concert with the literature, which has
shown in several different articles that immunohistochemistry can
be very effective in the detection of ALK rearrangement in lung
carcinomas (41–43).
OTHER BIOMARKERS
Currently, in over 50% of NSCLC’s, a driver oncogene can be
identified (18). In addition to the previously discussed ALK and
EGFR genes, several other potential targets have been uncovered
in NSCLC’s, including the V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS), the human epidermal growth factor
receptor 2 (HER2), reactive oxygen species 1 (ROS1), v-raf murine
sarcoma viral oncogene homolog B1 (BRAF), phosphoinositide-
3-kinase catalytic alpha polypeptide (PIK3CA), c-mesenchymal-
epithelial transition mitogen (c-MET ), activated protein kinase
(MAP2K1), fibroblast growth factor receptor (FGFR), discoidin
domain receptor 2 (DDR2), phosphatase and tensin homolog
(PTEN), protein kinase B (AKT), rearranged during transfec-
tion (RET), and the neuroblastoma RAS viral oncogene homolog
(NRAS). It is beyond the scope of this review to discuss each
in detail. Current general knowledge of the characteristics of
lung cancers carrying abnormalities in these genes has been
summarized in Table 1 (18, 20, 21, 28, 31, 33, 36, 37, 41,
44–72).
In conclusion, targeted therapy is already a reality for many
patients and it is certain that several other components will soon
follow to become valid options in the therapeutic arsenal of
oncologists. In view of the overwhelming amount of informa-
tion being constantly generated into the molecular derangements
associated with the development of lung cancer, it is not far-
fetched to expect that the current consensus guidelines will soon
become obsolete. As a pathologist, I witness on a daily basis a
continuous and inexorable change in our practice: our job no
longer ends with the histological diagnosis. In fact, molecular
profiling has become an integral part of the surgical pathology
report. It is crucial that us pathologists embrace this new format
of oncologic surgical pathology practice, and question ourselves,
after each new malignant diagnosis: “what should I do now that
might translate into a potential treatment alternative for this
patient?”
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